Puma Biotechnology | PBYI - Ordinary Share Capital


Puma Biotechnology reported $5K in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Exelixis USD 253.7M 8.78M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
MacroGenics USD 63.32M 60K Dec/2025
Moderna USD 391M 2M Sep/2025
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Takeda JPY 1.58B 241K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026